Revenue is effectively nil, with only $35 reported in 2026Q3 against R&D and SG&A of roughly $2.5M per quarter, leaving gross margin undefined in most periods and operating margin at -72266.9% in the latest quarter.
Rocket One Inc. (RKTO) annual income statement — 9-year revenue, gross profit & net income history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 |
|---|
| Sales/Revenue | 35 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 31.62K | 28.25K | 188 |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | 35 | 0 | 0 | 0 | 0 | 0 | 0 | -31.62K | -28.25K | -188 |
| Gross Margin % | 100% | - | - | - | - | - | - | - | - | - |
| Gross Profit Growth % | - | - | - | - | - | - | 100% | -11.93% | -14927.66% | - |
| Operating Expenses | 11.62M | 11.11M | 8.22M | 7.69M | 11.07M | 14.1M | 7.3M | 7.71M | 2.5M | 1.87M |
| OpEx % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Selling, General & Admin | 5.71M | 6.41M | 4.97M | 4.21M | 6.13M | 6.57M | 4.41M | 5.06M | 1.22M | 1.28M |
| SG&A % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Research & Development | 5.91M | 5.95M | 3.25M | 3.48M | 4.93M | 7.53M | 2.89M | 2.12M | 1.02M | 586.84K |
| R&D % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Other Operating Expenses | 0 | -1.25M | 0 | 0 | 0 | 0 | 0 | 0 | 258.71K | 0 |
| Operating Income | -11.62M | -11.11M | -8.22M | -7.69M | -11.07M | -14.1M | -7.3M | -7.71M | -2.5M | -1.87M |
| Operating Margin % | -33193174.29% | - | - | - | - | - | - | - | - | - |
| Operating Income Growth % | - | -35.24% | -6.8% | 30.48% | 21.53% | -93.12% | 5.35% | -209.15% | -33.34% | - |
| EBITDA | -11.64M | -12.47M | 0 | 260.73K | 0 | -14.31M | -7.3M | -7.71M | -2.49M | -1.87M |
| EBITDA Margin % | -33243440% | - | - | - | - | - | - | - | - | - |
| EBITDA Growth % | -48.07% | - | -100% | - | 100% | -96.05% | 5.35% | -209.26% | -33.29% | - |
| D&A (Non-Cash Add-back) | 26.42K | 0 | 8.22M | 7.95M | 11.07M | 0 | 1.04K | 1.23K | 1.22K | 188 |
| EBIT | -9.22M | -12.47M | -8.19M | -7.85M | -11.07M | -14.31M | -7.3M | -7.71M | -2.5M | -2.02M |
| Net Interest Income | 457 | 680 | 27.71K | 51.77K | -299.04K | 0 | 8 | 25 | 0 | 0 |
| Interest Income | 457 | 680 | 27.71K | 51.77K | 6.37K | 0 | 8 | 25 | 0 | 216K |
| Interest Expense | 0 | 0 | 0 | 0 | 305.41K | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | -276.89K | -1.36M | 27.13K | -153.15K | -306.4K | -212.26K | 104.16K | 10.36K | 0 | -144K |
| Pretax Income | -11.89M | -12.47M | -8.19M | -7.85M | -11.37M | -14.31M | -7.2M | -7.7M | -2.5M | -2.02M |
| Pretax Margin % | -33984280% | - | - | - | - | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | -0% |
| Net Income | -11.89M | -12.47M | -8.19M | -7.85M | -11.37M | -14.31M | -7.2M | -7.69M | -2.5M | -2.02M |
| Net Margin % | -33984280% | - | - | - | - | - | - | - | - | - |
| Net Income Growth % | 2.22% | -52.28% | -4.37% | 31.01% | 20.55% | -98.86% | 6.45% | -208.32% | -23.82% | - |
| Net Income (Continuing) | -11.89M | -12.47M | -8.19M | -7.85M | -11.37M | -14.31M | -7.2M | -7.7M | -2.5M | -2.02M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.48 | -0.90 | -1.28 | -2.30 | -9.50 | -16.03 | -14.56 | -20.99 | -6.62 | -5.24 |
| EPS Growth % | 44.83% | 29.69% | 44.35% | 75.79% | 40.74% | -10.1% | 30.63% | -217.07% | -26.34% | - |
| EPS (Basic) | - | -0.90 | -1.28 | -2.30 | -9.50 | -16.03 | -14.56 | -20.99 | -6.62 | -5.24 |
| Diluted Shares Outstanding | 24.71M | 13.81M | 6.38M | 3.41M | 1.2M | 893.2K | 494.51K | 366.58K | 376.98K | 384.48K |
| Basic Shares Outstanding | 24.71M | 13.81M | 6.38M | 3.41M | 1.2M | 893.2K | 494.51K | 366.58K | 376.98K | 384.48K |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
Quick answers to the most common questions about buying RKTO stock.
For fiscal year 2025, Rocket One Inc. (RKTO) reported total revenue of $0.0M.
Rocket One Inc. (RKTO) reported a net loss of $12.5M for the fiscal year ending 2025.
Key Metrics
Top Statement Risk
Persistent operating losses without revenue
Metrics are mathematically derived from official filings.
Revenue Base Too Thin to Assess
Based on reported figures, RKTO recorded only $35 in revenue in 2026Q3 with no revenue in the prior nine quarters shown, leaving growth rates undefined for most of the period under review.
The reported top line is effectively absent for nearly the entire ten-quarter window, so there is no meaningful growth trajectory to evaluate. The single $35 revenue entry in 2026Q3 is too small to indicate durable commercial traction and may reflect nominal or incidental sales rather than a commercial launch. Investors should monitor whether subsequent quarters produce recurring revenue before attributing any growth signal to the business.
Operating Spend Drives Losses Without Revenue Offset
As reported in the income statement, RKTO's R&D and SG&A expenses ranged from roughly $2.5M to $4.2M per quarter, producing operating losses in every period shown despite minimal sales.
Research and development and selling, general and administrative costs together account for the entire cost base, with COGS reported at zero throughout. The spend pattern suggests the company is funding development and overhead ahead of any revenue base, which is typical of early-stage biotech but leaves the cost structure dependent on external capital. Operating expense discipline cannot be assessed against revenue, so spending levels should be evaluated against pipeline milestones instead.
Net Losses Track Operating Losses Closely
Based on EDBL's reported figures, net income tracks operating income closely across the period, with reported EPS ranging from -$0.11 to -$0.36 and no evident non-operating offset.
Net loss figures sit very close to operating loss figures in each quarter, indicating limited non-operating items distorting reported earnings. Stock-based compensation appears in some periods but is small relative to total expenses, so it does not appear to be the primary driver of reported losses. The per-share loss figures also fluctuate with share count changes, which warrants further investigation into dilution.
Losses Persist With No Revenue Path Visible
Under a skeptical reading, RKTO's reported operating losses of $1.6M to $4.1M per quarter continue with no sustained revenue base, suggesting the investment case rests entirely on future commercialization not yet evidenced in the data.
The strongest challenge is that the income statement shows cumulative operating losses without any established revenue stream to offset them. Gross margin metrics are undefined because revenue is effectively zero, so the business model cannot be validated from reported figures. Investors may wish to weigh this against peer companies such as NRx Pharmaceuticals and Biofrontera, which report revenue alongside losses.